All In Biotech

Drug Trial Radar · NCT05614739

FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

FORAGER-1: A Phase 1, Open-Label, Multicenter Study of Vepugratinib (LY3866288; LOXO-435) in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer and Muscle Invasive Bladder Cancer With FGFR3 Alterations

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

677

Planned (sponsor's estimate)

Start

Jan 12, 2023

Primary completion

Jun 2027

Study completion Jun 2027

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Nov 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to learn more about the safety, side effects, and effectiveness of Vepugratinib by itself or when it is combined with other medicines that treat cancer. Vepugratinib may be used to treat cancer of the cells that line the urinary system and other solid tumor cancers that have a change in a particular gene (known as the FGFR3 gene). Study participation could last up to approximately 6 years, depending on which part of the study you join.

Conditions

  • Urinary Bladder Neoplasms
  • Neoplasm Metastasis
  • Ureteral Neoplasms

Interventions

  • VepugratinibDrug

    Oral

  • PembrolizumabDrug

    IV

  • enfortumab vedotinDrug

    IV

  • Trastuzumab DeruxtecanDrug

    IV

  • MidazolamDrug

    Oral

  • DigoxinDrug

    Oral

  • RosuvastatinDrug

    Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR)Time frame: Up to Approximately 30 Months or 2.5 Years
  2. Pharmacokinetics (PK) of Vepugratinib: Area Under the Concentration versus Time Curve (AUC)Time frame: Up to 2 Months
  3. PK of Midazolam, Rosuvastatin, and Digoxin Administered Alone and in the Presence of Vepugratinib: Area Under the Concentration versus Time Curve (AUC[0-inf])Time frame: Up to 2 Months
  4. Complete Response Rate (CRR) in Participants with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG IR NMIBC)Time frame: Up to approximately 24 months or 5 years

Locations

83 sites in 14 countries. Site status is shown where the registry gives one.

  • University of Arizona - Cancer Center

    Tucson, Arizona · Recruiting

  • City of Hope

    Duarte, California · Recruiting

  • University of California, Los Angeles (UCLA) - Division of Hematology-Oncology

    Los Angeles, California · Recruiting

  • University of California - Irvine

    Orange, California · Recruiting

  • University of California (UC) Davis Comprehensive Cancer Center

    Sacramento, California · Recruiting

  • Stanford Medicine Cancer Center

    Stanford, California · Recruiting

  • Advent Health

    Orlando, Florida · Recruiting

  • Emory University Hospital

    Atlanta, Georgia · Recruiting

  • The University of Chicago Medical Center (UCMC)

    Chicago, Illinois · Recruiting

  • Indiana University (IU) Melvin and Bren Simon Cancer Center

    Indianapolis, Indiana · Recruiting

  • Mary Bird Perkins Cancer Center

    Baton Rouge, Louisiana · Recruiting

  • Ochsner Clinic Foundation

    New Orleans, Louisiana · Recruiting

  • Johns Hopkins Kimmel Cancer Center

    Baltimore, Maryland · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • Washington University in St. Louis

    St Louis, Missouri · Recruiting

  • New York University (NYU)

    New York, New York · Recruiting

  • Weill Cornell Medicine

    New York, New York · Recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Recruiting

  • Columbia University

    New York, New York · Recruiting

  • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • University of Rochester - Wilmot Cancer Institute

    Rochester, New York · Recruiting

  • Montefiore Medical Center

    The Bronx, New York · Recruiting

  • University of North Carolina (UNC) - Chapel Hill

    Chapel Hill, North Carolina · Recruiting

  • University of Cincinnati Medical Center (UCMC)

    Cincinnati, Ohio · Recruiting

  • The Ohio State University (OSU)

    Columbus, Ohio · Recruiting

  • University of Oklahoma - Health Sciences Center

    Oklahoma City, Oklahoma · Recruiting

  • Penn Medicine Lancaster General Hospital - Ann B. Barshinger Cancer Institute

    Lancaster, Pennsylvania · Recruiting

  • University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • Thomas Jefferson University

    Philadelphia, Pennsylvania · Recruiting

  • Allegheny General Hospital

    Pittsburgh, Pennsylvania · Recruiting

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania · Recruiting

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina · Recruiting

  • Sarah Cannon and HCA Research Institute

    Nashville, Tennessee · Recruiting

  • Tennessee Oncology

    Nashville, Tennessee · Recruiting

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Recruiting

  • University of Texas Southwestern

    Dallas, Texas · Recruiting

  • Texas Oncology, P.A

    Dallas, Texas · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • University of Utah

    Salt Lake City, Utah · Recruiting

Showing 40 of 83 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.